<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04231994</url>
  </required_header>
  <id_info>
    <org_study_id>EXCHANGE 2786-2015</org_study_id>
    <nct_id>NCT04231994</nct_id>
  </id_info>
  <brief_title>Therapeutic Plasmaexchange in Early Septic Shock</brief_title>
  <acronym>EXCHANGE</acronym>
  <official_title>Prospective, Randomized, Single-center, Open-label, Parallel-group Trial Investigating the Efficacy of Therapeutic Plasma Exchange as an Adjunctive Strategy Against Early Septic Shock - Effect on Hemodynamics and Biochemical Markers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hannover Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sepsis is defined by the occurrence of critical organ dysfunction in the context of&#xD;
      infection. Unfortunately, its incidence appears to be rising, and the mortality of septic&#xD;
      shock remains extraordinary high (&gt; 60%). Death in sepsis arises from shock and multi organ&#xD;
      dysfunction that are - at least in part - triggered by an inadequate response of the host's&#xD;
      immune system to the infection. Given the injurious role of 1) this overwhelming immune&#xD;
      response and 2) the consumption of protective plasmatic factors (e.g. vWF cleaving proteases,&#xD;
      hemostatic factors etc.) while the disease is progressing the investigators hypothesize that&#xD;
      early therapeutic plasma exchange (TPE) in the most severely ill individuals might improve&#xD;
      hemodynamics, oxygenation and ultimately survival. This therapeutic strategy combines 2 major&#xD;
      aspects in 1 procedure: 1. removal of harmful circulating molecules and 2. replacement of&#xD;
      protective plasma proteins. The investigators designed the EXCHANGE trial to analyze in a&#xD;
      randomized fashion the benefit of TPE as an add-on treatment to state of the art standard&#xD;
      sepsis care. Only patients with early septic shock (&lt; 24 hrs) and high catecholamine doses&#xD;
      (norepinephrine &gt; 0.4 ug/kg body weight/min) will be included. Those in the treatment group&#xD;
      will receive 1 TPE within 2 hours following randomization. The primary outcome is&#xD;
      norepinephrine dose 6 hrs after randomization. The recruitment period is 2 years and will be&#xD;
      performed at the Hannover medical School University hospital in Germany. Secondary endpoints&#xD;
      (including organ dysfunction as well as biochemical markers of inflammation and coagulation)&#xD;
      will be assessed on day 1-8 and day 28 after TPE.&#xD;
&#xD;
      The investigators hope to demonstrate a potential benefit of an additive treatment approach&#xD;
      to improve the outcome of patients suffering from septic shock.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Actual">August 31, 2020</completion_date>
  <primary_completion_date type="Actual">July 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Norepinephrine dose</measure>
    <time_frame>6 hours after randomization</time_frame>
    <description>Vasopressor dose reduction as indicator of shock reversal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Sequential organ failure assessment (SOFA) score</measure>
    <time_frame>day 1-8 following randomization</time_frame>
    <description>SOFA score as indicator of organ dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percent change of ADAMTS-13 activity from baseline</measure>
    <time_frame>6 hours after randomization</time_frame>
    <description>(will only be analyzed in the Hannover cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percent change of activated Protein C activity from baseline</measure>
    <time_frame>6 hours after randomization</time_frame>
    <description>(will only be analyzed in the Hannover cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percent change of permeability factors angiopoietin-1, -2 and sTie-2 from baseline</measure>
    <time_frame>6 hours after randomization</time_frame>
    <description>permeability and anti-permeability factors (will only be analyzed in the Hannover cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28 day survival</measure>
    <time_frame>after 28 days following randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>TPE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>additive singular therapeutic plasma Exchange (TPE) using fresh frozen Plasma (FFP) as replacement fluid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SMT</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard medical Treatment (SMT) for septic shock following the present surviving sepsis guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TPE</intervention_name>
    <description>singular Therapeutic Plasma Exchange using fresh frozen Plasma as replacement fluid</description>
    <arm_group_label>TPE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Onset of septic shock within less than 24 hrs&#xD;
&#xD;
          -  Norepinephrine dose of ≥ 0.4 ug/kg/min bodyweight (target mean arterial pressure ≥ 65&#xD;
             mmHg) ≥ 30 min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age&lt;18 years and &gt; 80 years&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Known history of transfusion reactions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sascha David, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic for nephrology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Klaus Stahl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic for gastroenterology and hepatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <state>Lower Saxony</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/33471132/</url>
    <description>Related Info</description>
  </link>
  <results_reference>
    <citation>David S, Bode C, Putensen C, Welte T, Stahl K; EXCHANGE study group. Adjuvant therapeutic plasma exchange in septic shock. Intensive Care Med. 2021 Mar;47(3):352-354. doi: 10.1007/s00134-020-06339-1. Epub 2021 Jan 20.</citation>
    <PMID>33471132</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 13, 2020</study_first_submitted>
  <study_first_submitted_qc>January 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>February 6, 2021</last_update_submitted>
  <last_update_submitted_qc>February 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hannover Medical School</investigator_affiliation>
    <investigator_full_name>Stahl, Klaus Dr.</investigator_full_name>
    <investigator_title>Dr. Klaus Stahl, Fellow Gastroenterology and Critical Care Medicine</investigator_title>
  </responsible_party>
  <keyword>Septic shock</keyword>
  <keyword>Therapeutic plasma exchange</keyword>
  <keyword>Sepsis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>pre-defined substudies</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

